They recently had a court decision (plaintiff in patent infringement case) that went against them on their patent for the test. The judge said the patent was based on a natural process, so it can't be patented. Seems like she doesn't understand the patent was for a way to quantify the natural process. They are appealing the decision.
This is a situation of good product, but not necessarily a good investment.
Not a simple company to describe. Starting point is the primary market or noninvasive prenatal testing. Currently it is mainly high risk but all indication are it will eventually be all pregnancies. That will bring TAM to over $3b eventually. Sequenom was first mover and believe the held dominant patent so priced their test at high end. Now 4 companies in market with several others looking to launch in next yr. sequenom still market share leader but no longer dominant. Majority of tests processed are not covered by ins and even covered procedures are not being reimbursed due to Medicaid coding changes. Company revenues are on cash basis so financials and cash flow are terrible. Some day there will be some big winners in space but Q is how soon. Chart is terrible and shorts are very active. I'm long and very interested in next 2 calls to see whether they will need another cash raise
News 
Market Data 
Discover 
AI
